

In the Claims:

Please cancel Claims 2, 3, and 8, and amend Claims 1, 5, 9 and 10 as indicated in the attached Claims Listing.

In accordance with 37 C.F.R. §1.121 and the February 25, 2003 Official Gazette, a complete listing of all claims in the application is attached.

I. Remarks Concerning the Amendment

Claims 1, 4-7, 9 and 10 remain in the application; claims 2, 3, and 8 have been canceled; and Claims 1, 5, 9, and 10 have been amended.

Support for the amendment to Claim 1, which now includes elements previously found in Claims 2, 9, and 10, is found in the Specification, for example, in paragraphs [0010], [0029], and [0038]- [0064], and in Claims 1, 2, 8, 9 and 10 as originally filed.

Support for the amendment to Claim 5, which now includes the compound previously found in claim 3, is found in the Specification, for example, in paragraphs [0007] and [0029], and in Claims 1, 3 and 5 as originally filed.

Claims 9 and 10 have been amended to depend from Claim 1 instead of Claim 8 which has been canceled.

II. The §112, First Paragraph, Rejections

Claims 1, 4, and 6-10; and Written Description

Claims 1, 4, and 6-10 were rejected under 35 U.S.C. §112, first paragraph, as having an inadequate written description. In particular, the Office found an insufficient description for the functional term "a bFGF-active PAF antagonist."

Claim 1 has now been amended to reflect that the tumors being treated are of the lung and the prostate and the bFGF-active PAF antagonist is BN-50730. In light of this amendment, it is respectfully submitted that this rejection should be withdrawn, and Claim 1 and all the dependent claims should now be in condition for allowance.


Claims 1-8, and Enablement.

Claims 1-8 were rejected under 35 U.S.C. §112, first paragraph, for not being enabling for inhibiting tumors beyond carcinoma of the lung and prostate. In light of the amendment to Claim 1, it is respectfully submitted that this rejection should be withdrawn, and Claim 1 and all dependent claims are now in condition for allowance.

Conclusion

If any issues arise that may present an obstacle to allowance, the undersigned would welcome a telephone call to discuss such matters before further action is taken. Otherwise, allowance of Claims 1, 4-7, 9 and 10 at an early date is respectfully requested.

Respectfully submitted,



Bonnie J. Davis
Registration No. 41,699
Taylor, Porter, Brooks & Phillips
P.O. Box 2471
Baton Rouge, Louisiana 70821
(225) 387-3221

July 28, 2005

CLAIMS LISTING

1. (Currently amended) A method of inhibiting the growth of a tumor in a mammal, wherein the tumor is a carcinoma of the lung or of the prostate and wherein the growth of the tumor depends on basic fibroblast growth factor-stimulated angiogenesis, said method comprising administering to the mammal a therapeutically effective amount of a the bFGF-active PAF antagonist tetrahydro-4,7,8,10 methyl-1 (chloro-2 phenyl)-6 (methoxy-4 phenyl-carbomoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4[4,3-a]diazepine-1,4 ("BN-50730").
2. (Canceled)
3. (Canceled)
4. (original) The method of claim 1, additionally comprising the step of administering to the mammal another compound that inhibits tumor angiogenesis.
5. (Currently amended) The method of claim 4, wherein the additional compound is chosen from a group comprising CV 3988, WEB 2086, INF-2 α , TNP-470, endostatin, SU 5416, SU 6668, batimistat, angiostatin, and celecoxib.
6. (original) The method of claim 1, wherein said administering of the bFGF-active PAF antagonist is performed by subcutaneous injection, intravenous injection, intraperitoneal injection, or transdermal absorption.
7. (original) The method of claim 1, wherein the mammal is a human.

8. (Canceled)

9. (Currently amended) The method of claim 8 1, wherein the tumor is a form of carcinoma of the lung.

10. (Currently amended) The method of claim 8 1, wherein the tumor is a form of carcinoma of the prostate.